scholarly journals LyRIC indeterminate response and Immune‐mediated pseudoprogression of diffuse large B‐cell lymphoma following polatuzumab‐based salvage therapy

2020 ◽  
Vol 189 (6) ◽  
Author(s):  
Alexander T. J. Lee ◽  
Ayoma D. Attygale ◽  
Rajaei K. Sharma ◽  
Sunil Iyengar ◽  
Dima El‐Sharkawi ◽  
...  
Keyword(s):  
B Cell ◽  
Salvage Therapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Immune Mediated ◽  
Large B Cell

Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

2021 ◽  
pp. 1-4
Author(s):  
Xin Wang ◽  
Lacey McIntosh ◽  
William J. Selove ◽  
Jaroslav Zivny ◽  
Jan Cerny
Keyword(s):  
B Cell ◽  
Salvage Therapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma

2015 ◽  
Vol 57 (7) ◽  
pp. 1633-1639 ◽  
Author(s):  
Nadav Sarid ◽  
Erel Joffe ◽  
Lili Gibstein ◽  
Irit Avivi ◽  
Aaron Polliack ◽  
...  
Keyword(s):  
Elderly Patients ◽  
B Cell ◽  
Salvage Therapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Reduced Dose ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Nonregenerative immune-mediated anemia associated with a diffuse large B-cell lymphoma in a captive jaguar (Panthera onca )

2017 ◽  
Vol 46 (4) ◽  
pp. 597-604 ◽  
Author(s):  
Monika A. Keresztes ◽  
Manfred Henrich ◽  
Penelope Baloi ◽  
Sascha Gerst ◽  
Jens-Christian Rudnick ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Panthera Onca ◽  
Large B Cell Lymphoma ◽  
Immune Mediated ◽  
Large B Cell

scholarly journals Final results of a phase II trial of R-IDEA as salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma

2016 ◽  
Vol 27 ◽  
pp. vi321
Author(s):  
E. Kondo ◽  
K. Yamamoto ◽  
T. Masunari ◽  
J. Takizawa ◽  
K. Miura ◽  
...  
Keyword(s):  
B Cell ◽  
Phase Ii ◽  
Salvage Therapy ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

2008 ◽  
Vol 14 (3) ◽  
pp. 259-267 ◽  
Author(s):  
Tara Seshadri ◽  
John Kuruvilla ◽  
Michael Crump ◽  
Armand Keating
Keyword(s):  
B Cell ◽  
Salvage Therapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7517-7517 ◽  
Author(s):  
Jay Y. Spiegel ◽  
Saurabh Dahiya ◽  
Michael D. Jain ◽  
Loretta J. Nastoupil ◽  
Armin Ghobadi ◽  
...  
Keyword(s):  
B Cell ◽  
Salvage Therapy ◽  
Cell Lymphoma ◽  
Checkpoint Inhibitors ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Car T ◽  
Response Status ◽  
Poor Outcomes ◽  
Large B Cell

7517 Background: Axi-cel, an anti-CD19 CART cell therapy, achieved 83% ORR, 58% CR rate, with 39% PFS at 2 years in patients (pts) with relapsed refractory large B-cell lymphoma (LBCL) on the ZUMA-1 study (Locke, Lancet Oncology 2018). Data from a 17-center consortium showed response rates were similar in 274 pts treated with commercial axi-cel (Nastoupil, ASH 2018). Here, we performed retrospective analysis of outcomes in pts with progressive disease (PD) after axi-cel. Methods: Response status was determined by Cheson 2014 and reported as date of radiologic relapse. 274 pts were infused by December 26, 2018 with maximum follow-up of 14 months; 116 pts had PD as of Feb 1, 2019. Twelve sites provided additional data, detailing 85% of PD pts (n=99) with a median time to relapse of 54 days (IQR 16-120). Results: Pre axi-cel pt characteristics: median lines of therapy were 4 (range 2-11), 86% were Stage III/IV and 22% were ECOG >1. Following relapse, 60% (n=61) were biopsied and 70% (43/61) had CD19 expression measured. Thirty percent (13/43) were CD19 negative by: IHC (3/13), flow (2/13) or both (8/13). Seventy percent (n=71) received salvage therapy for PD. Median lines of salvage therapy was 1 (range 0-4). The most common therapies were Lenalidomide-based (30%), checkpoint inhibitors (30%), chemotherapy (20%) and radiation (10%). First salvage therapy ORR by regimen: checkpoint inhibitors = 24%, lenalidomide regimens = 20% and chemotherapy = 11%. One patient received allogeneic transplant. Twelve pts enrolled on clinical trial, with one receiving 2nd CAR-T. Median OS following relapse was 108 days (95% LCL 71). Nineteen pts relapsed <3 months after axi-cel and did not receive therapy with median OS 17 days (95% CI 7-49); 33 pts relapsed <3 months and received therapy with 114 day median OS (95% LCL 82). In contrast, 30 pts who relapsed >3 months post axi-cel and received therapy had estimated median OS >220 days (95% LCL 81). Conclusions: Patients with LBCL relapsing less than 3 months following axi-cel have extremely poor outcomes supporting the development of novel therapies. Therapy for relapse >3 months appears promising. JYS and SD contributed equally; APR, DBM and BTH contributed equally.

Sign in / Sign up

Export Citation Format

Share Document